D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function

The biology of VEGF and its receptors

Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591

Oxidants, oxidative stress and the biology of ageing

Finkel, T., & Holbrook, N. J. (2000) · Nature · doi:10.1038/35041687 · Cited by 9,413

Angiogenesis in cancer and other diseases

Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070

Integrated genomic analyses of ovarian carcinoma

Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735

A robust and high-throughput Cre reporting and characterization system for the whole mouse brain

Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. A., Gu, H., Ng, L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2467 · Cited by 6,907

Signal integration in the endoplasmic reticulum unfolded protein response

Ron, D., & Walter, P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2199 · Cited by 6,431

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857

IDH1 and IDH2 Mutations in Gliomas

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154

Preclinical Models of Low-Grade Gliomas

Dasgupta, P., Balasubramaniyan, V., de Groot, J. F., & Majd, N. (2023) · Cancers · doi:10.3390/cancers15030596 · Cited by 15

Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop

Peñas-Prado, M., Wu, J., Cahill, D. P., Brat, D. J., Costello, J., Kluetz, P. G., Cairncross, J. G., van den Bent, M. J., Verhaak, R. G. W., Aboud, O., et al. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz048 · Cited by 14

Insular primary glioblastomas with IDH mutations: Clinical and biological specificities

Hata, N., Hatae, R., Yoshimoto, K., Murata, H., Kuga, D., Akagi, Y., Sangatsuda, Y., Suzuki, S. O., Iwaki, T., Mizoguchi, M., et al. (2017) · Neuropathology · doi:10.1111/neup.12362 · Cited by 13

I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo

Jia, P., Wu, Y., Du, H., Yang, L., Zhang, Z., Ma, T., Sun, L., Yuan, S., Lu, L., & Zha, X. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105072 · Cited by 13

Emerging Roles of Wild-type and Mutant IDH1 in Growth, Metabolism and Therapeutics of Glioma

Garrett, M. C., Fujii, Y., Osaka, N., Ito, D., Hirota, Y., & Sasaki, A. T. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.gliomas.2021.chapter4 · Cited by 14

An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing

van Oosterwijk, J. G., Plass, J. R. M., Meijer, D., Que, I., Karperien, M., & Bovée, J. V. M. G. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1670-y · Cited by 13

Astrocytic gliomas WHO grades II and III

Berger, M. S., Hervey‐Jumper, S. L., & Wick, W. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00021-9 · Cited by 13

Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis

Tiburcio, P. D. B., Xiao, B., Berg, S., Asper, S., Lyne, S. B., Zhang, Y., Zhu, X., Yan, H., & Huang, L. E. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1800-0 · Cited by 12

Rediscovering Potential Molecular Targets for Glioma Therapy Through the Analysis of the Cell of Origin, Microenvironment and Metabolism

Guo, X., Wang, T., Huang, G., Li, R., Costa, C. D., Li, H., Lv, S., & Li, N. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210504091722 · Cited by 13

Current development and future perspective of IDH1 inhibitors in cholangiocarcinoma

Adeva, J. (2021) · Liver Cancer International · doi:10.1002/lci2.43 · Cited by 12

The Emerging Nexus of Active DNA Demethylation and Mitochondrial Oxidative Metabolism in Post-Mitotic Neurons

Meng, H., Chen, G., Gao, H., Song, X., Shi, Y. S., & Cao, L. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151222604 · Cited by 12

The clinical characteristics and prognostic factors of multiple lesions in glioblastomas

Tunthanathip, T., Sangkhathat, S., Tanvejsilp, P., & Kanjanapradit, K. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.105891 · Cited by 12

Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study

Xu, T., Yang, J., Li, D., Challa, M., Zou, C., Deng, P., Zhang, S., & Xu, B. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116610 · Cited by 11

IDH1 Mutations Disrupt Blood, Brain, and Barriers

Shih, A. H., & Levine, R. L. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.022 · Cited by 11

Featuring how calcium channels and calmodulin affect glioblastoma behavior. A review article

Azab, M. A., Alomari, A., & Azzam, A. Y. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100255 · Cited by 11

Isocitrate dehydrogenase mutations: new opportunities for translational research

Keum, Y., & Choi, B. Y. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.5.021 · Cited by 11

Lactate-Mediated Epigenetic and Immunometabolic Reprogramming in Glioma: An Emerging Axis Linking Metabolism to Tumor Progression

Xie, X., Zhou, W., Ku, Y., Li, S., Yang, Y., Hao, X., & Chen, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13123041 · Cited by 11

Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers

Thamim, M., Agrahari, A. K., Gupta, P. K., & Thirumoorthy, K. (2023) · Molecules · doi:10.3390/molecules28052315 · Cited by 10

In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy development

Figg, J., Chen, D., Font, L. F., Flores, C., & Jin, D. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae131 · Cited by 11

IDH1 regulates phospholipid metabolism in developing astrocytes

Bogdanovic, E., Sadri, A.-R., Catapano, M. S., Vance, J. E., & Jeschke, M. G. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.09.015 · Cited by 11

Effects of deranged metabolism on epigenetic changes in cancer

Chandra, V., & Hong, K. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0561-3 · Cited by 11

Differentiation therapy for IDH1/2 mutant malignancies

Garrett-Bakelman, F. E., & Melnick, A. M. (2013) · Cell Research · doi:10.1038/cr.2013.73 · Cited by 10

In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation

Robinson, G. L., Philip, B., Guthrie, M. R., Cox, J. E., Robinson, J., VanBrocklin, M. W., & Holmen, S. L. (2016) · Cancer Research Frontiers · doi:10.17980/2016.311 · Cited by 10

Metabolic functions of misunderstood D-2-hydroxyglutarate

Liu, Y., Kang, Z., Zhang, W., Ma, C., Xu, P., & Gao, C. (2024) · The Innovation Life · doi:10.59717/j.xinn-life.2024.100101 · Cited by 10

IDH1R132H is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment

Tiburcio, P. D. B., Xiao, B., Chai, Y., Asper, S., Tripp, S. R., Gillespie, D. L., Jensen, R. L., & Huang, E. L. (2018) · Oncotarget · doi:10.18632/oncotarget.26203 · Cited by 9

Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration

Kang, S., Kwon, H. N., Kang, S., & Park, S. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.073 · Cited by 9

An IDH1-mutated primary gliosarcoma: case report

Hsieh, J. K., Hong, C. S., Manjila, S. V., Cohen, M. L., Lo, S. S.-M., Rogers, L. R., & Sloan, A. E. (2016) · Journal of neurosurgery · doi:10.3171/2016.2.jns151482 · Cited by 9

C-13 Hyperpolarized MR Spectroscopy for Metabolic Imaging of Brain Tumors

Viswanath, P., Li, Y., & Ronen, S. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-27359-0_12 · Cited by 8

Understanding the molecular profiling of diffuse gliomas classification: A brief overview

Ordóñez-Rubiano, E. G., Baldoncini, M., Cómbita, A. L., Payán‐Gómez, C., Gómez-Amarillo, D. F., Hakim, F., Figueredo, L. F., Forlizzi, V., Castillo-Rangel, C., Luzzi, S., et al. (2023) · Surgical Neurology International · doi:10.25259/sni_209_2023 · Cited by 9

Chiral discrimination in a mutated IDH enzymatic reaction in cancer: a computational perspective

Thamim, M., & Thirumoorthy, K. (2020) · European Biophysics Journal · doi:10.1007/s00249-020-01460-x · Cited by 8

Preclinical modeling of lower-grade gliomas

Tang, L. W., Mallela, A. N., Deng, H., Richardson, T. E., Hervey‐Jumper, S. L., McBrayer, S. K., & Abdullah, K. G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1139383 · Cited by 8

An overview of current and future treatment options for chondrosarcoma

Su, C., Fong, Y., & Tang, C. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.874280 · Cited by 8

Beyond the Oncogene Revolution: Four New Ways to Combat CancerPreprint

Berger, T., Saunders, M. E., & Mak, T. W. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031161 · Cited by 8

Generation of induced neural stem cells with inducible IDH1R132H for analysis of glioma development and drug testing

Rosiak, K., Grot, D., & Rieske, P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239325 · Cited by 6

Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future

Gan, H. K., Day, B. W., Harrup, R. A., Johns, T. G., Lwin, Z., Scott, A. M., Sim, H., & Koh, E. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01394-5 · Cited by 8

Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma

Shayanfar, N., Zare‐Mirzaie, A., Mohammadpour, M., Jafari, E., Mehrtash, A., Emtiazi, N., & Tajik, F. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04336-z · Cited by 8

IDH-Mutant Gliomas

Tateishi, K., & Yamamoto, T. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84543 · Cited by 7

Metabolic reprogramming of pyruvate dehydrogenase is essential for the proliferation of glioma cells expressing mutant IDH1

Viswanath, P., & Ronen, S. M. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1077922 · Cited by 7

Roles of the oncometabolite enantiomers of 2-hydroxyglutarate and their metabolism by diverse dehydrogenases

Garcia, I., Cornely, K. A., Peterson, C. N., & Berkmen, M. B. (2024) · Essays in Biochemistry · doi:10.1042/ebc20230077 · Cited by 8

IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis

Gao, Y., de Wit, M., Struys, E. A., van der Linde, H. C. Z., Salomons, G. S., Lamfers, M. L. M., Willemsen, R., Smitt, P. A. E. S., & French, P. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199737 · Cited by 6

Discovery and structure-activity relationship study of novel hydantoin-based inhibitors targeting mutant isocitrate dehydrogenase 1 (mIDH1)

Luo, D., Zhang, M., Liang, Z., Gan, L., He, Y., & Zhang, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117945 · Cited by 5

Rodent models of tumours of the central nervous system

Brandner, S. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13729 · Cited by 5

Loss of the mitochondrial carrier, SLC25A1, during embryogenesis induces a unique senescence program controlled by p53Preprint

Kasprzyk-Pawelec, A., Tan, M., Rahhal, R., McIntosh, A. T., Fernandez, H. R., Mosaoa, R., Jiang, L., Pearson, G. W., Glasgow, E. F., Vockley, J. E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.18.549409 · Cited by 5

Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood

Huse, J. T. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.005 · Cited by 4

Animal Models in Glioblastoma: Use in Biology and Developing Therapeutic Strategies

Schuhmacher, A. J., & Squatrito, M. (2017) · Current cancer research · doi:10.1007/978-3-319-56820-1_9 · Cited by 4

mIDH-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation

Wiehle, L., Raddatz, G., Pusch, S., Gutekunst, J., von Deimling, A., Rodríguez‐Paredes, M., & Lyko, F. (2017) · Cell Stress · doi:10.15698/cst2017.10.106 · Cited by 4

The immune regulation of BCL3 in glioblastoma with mutated IDH1

Fan, S., Wu, N., Chang, S.-C., Chen, L., & Sun, X. (2022) · Aging · doi:10.18632/aging.204048 · Cited by 4

Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma

Shi, D. D., Lee, J. H., Wang, A. C., Khanal, J., Gao, W., Kaelin, W. G., & McBrayer, S. K. (2023) · STAR Protocols · doi:10.1016/j.xpro.2023.102281 · Cited by 4

Immunometabolic Regulation of Anti-Tumor T-Cell Responses by the Oncometabolite D-2-Hydroxyglutarate

Böttcher, M., & Mougiakakos, D. (2019) · Immunometabolism · doi:10.20900/immunometab20190007 · Cited by 4

IDH1 Mutations in Glioma: Considerations for Radiotracer Development.

Chitneni, S. K. (2016) · PubMed · Cited by 4

Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH‐Mutant Glioma

Yang, J., Yang, H., Yuan, Y., Zhang, C., Fu, Z., Chen, Y., Xiong, Y., Chen, S., Ling, K., Liu, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202503866 · Cited by 4

The Warburg effect and beyond: Glycolytic reprogramming in cancer progression and emerging therapeutic strategies

Long, Y., Xu, J., Xu, Z., Su, Z., Li, W., & Li, J. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119692 · Cited by 3

Prediction of Tumor Development and Urine-Based Liquid Biopsy for Molecule-Targeted Therapy of Gliomas

Kurimoto, M., Rockenbach, Y., Kato, A., & Natsume, A. (2023) · Genes · doi:10.3390/genes14061201 · Cited by 3

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1 -mutant gliomaPreprint

Kayabölen, A., Yilmaz, E., Şahin, G. N., Seker-Polat, F., Cingöz, A., Isik, B., Acar, S., Wakimoto, H., Cahill, D. P., Solaroğlu, İ., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.26.400234 · Cited by 5

Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models

Schwartz, A. V., Chao, G., Robinson, M., Conley, B. M., Adam, M. A. A., Wells, G. A., Hoang, A. D., Albekioni, E., Gallo, C., Weeks, J. L., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108477 · Cited by 2

HOT mutation screening in human glioblastomas

Krell, D., Mulholland, P. J., Stebbing, J., Tomlinson, I. P. M., & Bardella, C. (2015) · Future Science OA · doi:10.4155/fso.15.20 · Cited by 2

The Distribution and Significance of IDH Mutations in Gliomas

Tran, N. T. N. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.97380 · Cited by 2

BAT mitochondria: whitening meets softening

Mori, M. P., Lozoya, O. A., & Santos, J. H. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01319-5 · Cited by 2

Brain Tumor Stem Cells

Bayin, N. S., Modrek, A. S., & Placantonakis, D. G. (2014) · Molecular pathology library · doi:10.1007/978-1-4939-1830-0_2 · Cited by 2

What's New in Grade II and Grade III Gliomas?

Wick, W., & Miller, J. J. (2018) · Seminars in Neurology · doi:10.1055/s-0037-1620275 · Cited by 2

Mouse Models of Diffuse Lower-Grade Gliomas of the Adult

Archontidi, S., Joppé, S. E., Khenniche, Y., Bardella, C., & Huillard, E. (2020) · Neuromethods · doi:10.1007/978-1-0716-0856-2_1 · Cited by 3

Mutant IDH silences GSX2 to reprogram neural progenitor cell fate and promote gliomagenesisPreprint

Xiao, Y., Shi, D. D., Guo, L., Neumann, E., Levitt, M. M., Kaphle, P., Shipman, T. E., Li, H., Cai, F., Ramirez, D. M. O., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.12.667486 · Cited by 4

The development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132H

Mehjardi, N., Keßler, J., Sanin, A. Y., Picard, D. J., Westhoff, P., Nickel, A., Uhlmann, C., Shi, W., Steiger, H., Remke, M., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01747-w · Cited by 1

Zinc Protoporphyrin Functions as a Ferroptosis Inducer to Activate Heme-BACH Axis and Potently Suppress IDH1-Mutant Gliomas

Yang, Y., Nie, Y., Wu, R., Han, R., Zhao, Y., Yang, R., Yuan, Y., Gao, X., Chen, H., Zhang, F. L., et al. (2025) · Antioxidants and Redox Signaling · doi:10.1177/15230864251394709 · Cited by 1

Targeted Therapy of IDH1-Mutated Tumors

Clark, O., & Grommes, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-49864-5_10 · Cited by 1

Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities

Huang, F., Tian, T., Wu, Y., Che, J., Yang, H., & Dong, X. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201130102724 · Cited by 1

Cancer Metabolism

Wahl, D. R., & Venneti, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-61401-4_6 · Cited by 1

IDH-mutant inhibitors enhance the sensitivity of IDH1-mutant gliomas to cysteine-methionine deprivation and ferroptosisPreprint

Mela, A., Brand, A. L., Mahajan, A., Dovas, A., Humala, N., Kanangat, S., Kleinstein, A., Leskinen, S., Nguyen, T. T., Gao, Q., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702627 · Cited by 1

Immature disruption

McCarthy, N. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3377

Epigenetic basis for the oncogenic potential of IDH mutations

Lü, C. (2013)

Tumor-Specific Approach: Oligodendroglioma (IDH1 Mutated, 1p/19q Deleted)

Leyrer, C. M., Murphy, E. S., & Ahluwalia, M. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-49864-5_17

Dissemination of Diffuse Low-Grade Gliomas: Tools and Molecular Insights

Leventoux, N., Hassani, Z., & Hugnot, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-55466-2_7

Molecular Drivers in Chondrosarcoma

de Jong, Y., & Bovée, J. V. M. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804257-1.00004-9

Animal models of primary brain tumors

Kolb, B. L., Fadel, H. A., Klinger, N. V., & Mittal, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814704-7.00007-6

Tfh Lymphoma: Analysis of a RHOA Mutation & Establishment of a Pre-Clinical Model

Allchin, R. L. (2019) · Figshare

IDH1 Mutation Enhances Catabolic Flexibility and Mitochondrial Dependencies to Favor Drug Resistance in Acute Myeloid LeukemiaPreprint

Stuani, L., Sabatier, M., Millard, P., Palama, T., Poupin, N., Saland, E., Bosc, C., Tonini, L., Gales, L., Montersino, C., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3255557

Astrocytes in glioblastoma : enhancers of tumor growth, predictors of patient survival and potential therapeutic targets

Mega, A. (2020) · Figshare

Immunohistochemical classification of diffuse gliomas. Doctoral Thesis

Jakovļevs, A. (2021) · doi:10.25143/prom-rsu_2021-04_dt

Epigenetic heterogeneity in primary bone cancers

Peneder, P., Tomazou, E. M., & Tötzl, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00039-6

Epigenetik in der Onkologie

Kubicek, S., Schirghuber, E., Klepsch, F., Colinge, J., & Kubicek, S. (2012) · Wiener klinisches Magazin · doi:10.1007/s00740-012-0059-2

Title: (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Tumorigenesis in IDH-Mutant CancersPreprint

Gunn, K., Myllykoski, M., Cao, J. Z., Huang, B., Rouaisnel, B., Diplas, B. H., Levitt, M. M., Looper, R., Doench, J. G., Ligon, K. L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3992089

Faculty Opinions recommendation of Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma.

MacKintosh, C. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.729073989.793538582

Biochemical and Genetic Markers in Neurological Trauma and Tumors: Review Article

Ashraf, O., Saleem, T. H., Elsadek, B., Hamdan, A. R. K., & Hassan, M. H. (2022) · Asian Journal of Biochemistry Genetics and Molecular Biology · doi:10.9734/ajbgmb/2022/v11i230260

The development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132HPreprint

Kahlert, U. D., Mehjardi, N., Sanin, A. Y., Picard, D. J., Westhoff, P., Nickel, A., Uhlmann, C., Shi, W., Steiger, H.-J., Remke, M., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3216060/v1

Catalytically distinct IDH1 mutants tune phenotype severity in tumor modelsPreprint

Adam, M. A. A., Robinson, M., Schwartz, A. V., Wells, G. A., Hoang, A. D., Albekioni, E., Gallo, C., Chao, G., Weeks, J. L., Quichocho, G., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.22.590655

Isocitrate dehydrogenase 1 gene mutations: a case review unveiling its biological impact on disease progression, prognosis and treatment in Chilean patients

de Mayo, T., García‐Bloj, B., Godoy, J. A., Chávez, F. S., Retamal, I. N., Gómez‐Valenzuela, F., Silva, I., Muñoz‐Medel, M., Sánchez, C., Pinto, F., et al. (2025) · BJR|case reports · doi:10.1093/bjrcr/uaaf019

Identification and structure-activity relationship optimization of dibromoacetophenones as novel mIDH1 inhibitors

Li, C., Yang, M., Cui, Z., Yan, H., Ou, J., Xu, B., Wang, Y., He, Y., & Zhang, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118050

Lysine- R 2HGylation identified as a post-translational modification in R 2HG-elevated cancersPreprint

Zhao, Q., Huang, P., Yuan, C., Xia, P., Gu, Q., Yang, T., Li, X., Tian, R., & Yang, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.03.680013

Additional file 1 of ROS attenuates TET2-dependent ZO-1 epigenetic expression in cerebral vascular endothelial cells

Wang, L., Mao, B., Fan, K., Sun, R., Zhang, J., Liang, H., & Liu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21069708

Tumeurs cérébrales de bas grade : élaboration de modèles in vitro et in vivo pour le développement de thérapies innovantes

Azar, S. (2017) · theses.fr (ABES) · doi:10.70675/bf84bd7bz42b1z4285z8aaaz42005d696ede

Characterization of cellular heterogeneity in Diffuse Low Grade Glioma

Augustus, M. (2020) · theses.fr (ABES) · doi:10.70675/037c23a4z44ddz4bb7z999ezb0c178c35170

Développement de radiotraceurs spécifiques des isocitrates déshydrogénases mutées (mIDH1) pour l'imagerie TEP/TEMP des tumeurs solides

Arnaud, L. (2025) · theses.fr (ABES) · doi:10.70675/a018d358z4613z4bb6zb6ddz3016efbdaa6d

Etude de l'hétérogénéité du microenvironnement et des cellules tumorales dans le lymphome TFH

Mboumba, D. L. (2024) · theses.fr (ABES) · doi:10.70675/ab609d7azbd90z40daza2b9za9670f82c1f5

Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma

Shi, D. D., Fernández, E. C., Puliyappadamba, V. T., Lanman, T. A., Xiao, Y., Wen, Z., Minor, M., Prost, D. M., Lasica, A. B., Cai, F., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aee5876 · Cited by 1

Molecular landscape of chondrosarcoma: From tumor biology to therapeutic vulnerabilities

Belluzzi, E., Pozzuoli, A., Trovarelli, G., Angelini, A., & Ruggieri, P. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189736

BindingDB Entry 50006775: Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.

BindingDB (2021) · UC San Diego · doi:10.7270/q2gb2793

BindingDB Entry 50022115: Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study.

BindingDB (2025) · UC San Diego · doi:10.7270/q2cr6037

Immature disruption

McCarthy, N. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3377

D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma

Pusch, S., Schweizer, L., Beck, A.-C., Lehmler, J.-M., Weißert, S., Balß, J., Miller, A. K., & von Deimling, A. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-19 · Cited by 93

Mutant IDH1 Promotes Glioma Formation In Vivo

Philip, B., Yu, D. X., Silvis, M. R., Shin, C., Robinson, J. P., Robinson, G. L., Welker, A., Angel, S. N., Tripp, S. R., Sonnen, J. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.133 · Cited by 112

IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo

Bralten, L. B. C., Kloosterhof, N. K., Balvers, R. K., Sacchetti, A., Lapre, L., Lamfers, M. L. M., Leenstra, S., de Jonge, H. R., Kros, J. M., Jansen, E. E. W., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22390 · Cited by 148

Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas

Jin, G., Reitman, Z. J., Duncan, C. G., Spasojević, I., Gooden, D. M., Rasheed, B. A., Yang, R. R., Lopez, G. Y., He, Y., McLendon, R. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2852 · Cited by 130